Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
The immunotherapeutic effect of human recombinant interleukin 2 was examined with a panel of MC-induced murine sarcomas carrying individual tumour-specific transplantation antigens. Repeated peritumoral injections of RIL-2 inhibited growth of five (MC11, MC13, MC14, MC15, MC16) out of six sarcomas in syngeneic mice. The sixth murine sarcoma (MC12) was resistant to the tumour-inhibitory effect of human recombinant IL-2 as well as to the tumour-inhibitory effect of murine and rat lymphoid IL-2 preparations. Since the IL-2-sensitive and IL-2-resistant sarcomas were induced with MC in mice of identical genotype and share most of their characteristics, they represent a useful model for investigation of structural target cell determinants and functional target cell properties responsible for the sensitivity of tumours to the immunotherapeutic effects of IL-2.
D000287:Administration, Topical; D000818:Animals; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000627:therapeutic use; D051379:Mice; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012513:Sarcoma, Experimental / Q000628:therapy*
D007376:Interleukin-2; D011994:Recombinant Proteins